ArticleGhana medical journal2025
Post-market quality monitoring of medicines in Christian Health Association of Ghana health institutions.
Article in Ghana medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the quality of selected frequently used medicines in CHAG facilities in a LMIC country setting. Design: Quality testing of collected samples of generic medicines in health facility pharmacies. Setting and participating facilities: The study evaluated the quality of 639 representative samples of 14 generic products using a TruScan Raman (RM) analyser and Minilab in 62 CHAG facilities across five administrative regions of Ghana. Results: Out of 639 samples of various branded generics of the 14 product samples tested in the field using the Truscan RM analyser, 210 products (32.8%) failed the test. All samples from ceftriaxone injection 1 g, ciprofloxacin 500 mg, metronidazole 200 mg, and metformin 500 mg passed the Truscan RM test. High passes were also recorded for paracetamol 500 mg (96.6%), artemether/lumefantrine 80/480 mg (95.8%), and oral rehydration salts (94%). Conversely, all the forty-two (42) samples obtained and tested for flucloxacillin 250 mg failed the Truscan analyser test. Relatively high failures were also recorded for lisinopril 10 mg (90.5%) and albendazole 400 mg (89.8%). All samples submitted for secondary screening using Minilab analysis showed the presence of their respective active pharmaceutical ingredients as indicated on their respective labels. Conclusion: The Truscan/Minilab combination is reasonably affordable and efficient for undertaking post-market monitoring of the quality of essential medicines in Ghanaian health facilities. For future application of Truscan, a check of standard spectra is essential, and the choice of tracer medicines should include those with limited fluorescence materials in formulations and a relatively high percentage of active ingredients. Funding: This study was funded by Pharmaccess Foundation Ghana and the Netherlands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.